CO2023003656A2 - Métodos para el tratamiento de enfermedades cardiovasculares con ciclodextrinas - Google Patents

Métodos para el tratamiento de enfermedades cardiovasculares con ciclodextrinas

Info

Publication number
CO2023003656A2
CO2023003656A2 CONC2023/0003656A CO2023003656A CO2023003656A2 CO 2023003656 A2 CO2023003656 A2 CO 2023003656A2 CO 2023003656 A CO2023003656 A CO 2023003656A CO 2023003656 A2 CO2023003656 A2 CO 2023003656A2
Authority
CO
Colombia
Prior art keywords
disease
atherosclerosis
increase
control
level
Prior art date
Application number
CONC2023/0003656A
Other languages
English (en)
Spanish (es)
Inventor
Diana Kerwin
Jason Camm
Original Assignee
Beren Therapeutics P B C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beren Therapeutics P B C filed Critical Beren Therapeutics P B C
Publication of CO2023003656A2 publication Critical patent/CO2023003656A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CONC2023/0003656A 2020-08-27 2023-03-23 Métodos para el tratamiento de enfermedades cardiovasculares con ciclodextrinas CO2023003656A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063071257P 2020-08-27 2020-08-27
PCT/US2021/048084 WO2022047249A1 (en) 2020-08-27 2021-08-27 Methods for the treatment of cardiovascular disease with cyclodextrins

Publications (1)

Publication Number Publication Date
CO2023003656A2 true CO2023003656A2 (es) 2023-08-09

Family

ID=80353287

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0003656A CO2023003656A2 (es) 2020-08-27 2023-03-23 Métodos para el tratamiento de enfermedades cardiovasculares con ciclodextrinas

Country Status (14)

Country Link
US (2) US20240000826A1 (cg-RX-API-DMAC10.html)
EP (1) EP4203974A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023543131A (cg-RX-API-DMAC10.html)
KR (1) KR20230104119A (cg-RX-API-DMAC10.html)
CN (1) CN116322644A (cg-RX-API-DMAC10.html)
AU (1) AU2021331487A1 (cg-RX-API-DMAC10.html)
CA (1) CA3189915A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023003656A2 (cg-RX-API-DMAC10.html)
CR (1) CR20230135A (cg-RX-API-DMAC10.html)
IL (1) IL300805A (cg-RX-API-DMAC10.html)
JO (1) JOP20230043A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023002418A (cg-RX-API-DMAC10.html)
PE (1) PE20231169A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022047249A1 (cg-RX-API-DMAC10.html)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877778A (en) * 1987-07-01 1989-10-31 The Children's Medical Center Corporation Method of enhancing lipophile transport using cyclodextrin derivatives
WO2013155485A2 (en) * 2012-04-13 2013-10-17 Alessia Fornoni Method of using cyclodextrin

Also Published As

Publication number Publication date
EP4203974A1 (en) 2023-07-05
CA3189915A1 (en) 2022-03-03
IL300805A (en) 2023-04-01
CN116322644A (zh) 2023-06-23
KR20230104119A (ko) 2023-07-07
MX2023002418A (es) 2023-07-11
EP4203974A4 (en) 2024-08-07
JP2023543131A (ja) 2023-10-13
JOP20230043A1 (ar) 2023-02-27
CR20230135A (es) 2023-07-19
AU2021331487A1 (en) 2023-03-16
WO2022047249A1 (en) 2022-03-03
US20240000826A1 (en) 2024-01-04
US20230091966A1 (en) 2023-03-23
PE20231169A1 (es) 2023-07-26

Similar Documents

Publication Publication Date Title
Mehta et al. Contemporary approach to cardiogenic shock care: a state-of-the-art review
Tibaut et al. Pathophysiology of myocardial infarction and acute management strategies
Bell et al. The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society guidelines
Burchell et al. Arteriovenous anastomosis: is this the way to control hypertension?
Palazzuoli et al. Loop diuretics in acute heart failure: beyond the decongestive relief for the kidney
Tayebjee et al. Abnormal circulating levels of metalloprotease 9 and its tissue inhibitor 1 in angiographically proven peripheral arterial disease: relationship to disease severity
Mason Takayasu arteritis: surgical interventions
JOP20230130A1 (ar) أحماض بيرازولو بيبريدين كربوكسيليك تحمل بدائل
Oktay et al. Current perspectives on systemic hypertension in heart failure with preserved ejection fraction
Daugherty et al. Recent highlights of ATVB: aneurysms
Gladysheva et al. Falling corin and ANP activity levels accelerate development of heart failure and cardiac fibrosis
CR20230135A (es) Métodos para el tratamiento de enfermedades cardiovasculares con ciclodextrinas
Jefferies et al. Cardorenal syndrome: an emerging problem in pediatric critical care
Nakahashi et al. Gout, uric acid, and coronary artery disease
Nyvad et al. With a little help from my friends: the role of the renal collateral circulation in atherosclerotic renovascular disease
AR073233A1 (es) Uso de inhibidores de epoxido hidrolasa soluble, como por ejemplo 1-adamantil-3-(1-acetilpiperidin-4-il) urea, en el tratamiento de enfermedades vasculares inflamatorias, metodo para identificar una enfermedad tratable y stent
Hothi Managing heart failure in dialysis patients
Ledingham Heyde's syndrome: exploring the link between aortic stenosis and an acquired bleeding disorder
Thaker et al. Acute circulatory collapse and advanced therapies in patients with COVID-19 infection
Nakamura et al. Symptomatic peripheral artery disease is associated with decreased long-term survival after coronary artery bypass: a contemporary retrospective analysis
Park Neutrophil-to-lymphocyte ratio for risk assessment in coronary artery disease and carotid artery atherosclerosis
Changal et al. Coronary artery aneurysms in ST-elevation myocardial infarction (from a United States based national cohort)
Konovalova et al. The impact of concomitant anemic syndrome on the clinical course of coronary artery disease
Shukla et al. Cirrhotic cardiomyopathy is less prevalent in patients with Budd-Chiari syndrome than cirrhosis of liver
Fu et al. Drug-coated balloons: A better revascularization strategy in patients with multivessel coronary artery disease undergoing one-stop hybrid coronary revascularization surgery